<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MULTAQ - dronedarone tablet, film coated </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ.<br> <br>MULTAQ (dronedarone) Tablets<br>Initial U.S. Approval: 2009  </div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: INCREASED RISK OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">STROKE</span> AND <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span> IN PATIENTS WITH <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">DECOMPENSATED HEART FAILURE</span> OR PERMANENT <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">ATRIAL FIBRILLATION</span></span></h1>
<h1 class="Warning"> </h1>
<p class="Highlighta"><span class="Bold">MULTAQ is contraindicated in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with recent decompensation requiring hospitalization or NYHA Class IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. MULTAQ doubles the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in these patients (<a href="#S4">4</a>, <a href="#S5.1">5.1</a>, <a href="#S14.3">14.3</a>).</span> </p>
<p class="Highlighta"><span class="Bold">MULTAQ is contraindicated in patients in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (AF) who will not or cannot be cardioverted into normal sinus rhythm. In patients with permanent AF, MULTAQ doubles the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#S4">4</a>, <a href="#S5.2">5.2</a>,<a href="#S14.4">14.4</a>)</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="ic13f7982-27c0-443f-8571-964cc10d4bd6"></a><table width="85%">
<col align="left" valign="top" width="85%">
<col align="right" valign="top" width="15%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">•  Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span> (<a href="#S5.5">5.5</a>) </td>
<td align="right">02/2011 </td>
</tr>
<tr>
<td align="left">•  Warnings and Precautions, Increase in Creatinine after Treatment Initiation (<a href="#S5.8">5.8</a>)	</td>
<td align="right">08/2011</td>
</tr>
<tr class="Botrule Last">
<td align="left">•  Indications and Usage, (<a href="#S1">1</a>), Contraindications (<a href="#S4">4</a>), Warnings and Precautions (<a href="#S5.1">5.1</a>, <a href="#S5.2">5.2</a>, <a href="#S5.3">5.3</a>, <a href="#S5.4">5.4</a>) <a href="#S5.5">5.5</a>)</td>
<td align="right">xx/2011</td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: INCREASED RISK OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">STROKE</span> AND <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span> IN PATIENTS WITH <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">DECOMPENSATED HEART FAILURE</span> OR PERMANENT <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">ATRIAL FIBRILLATION</span></span></h1>
<h1 class="Warning"> </h1>
<p class="Highlighta"><span class="Bold">MULTAQ is contraindicated in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with recent decompensation requiring hospitalization or NYHA Class IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. MULTAQ doubles the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in these patients (<a href="#S4">4</a>, <a href="#S5.1">5.1</a>, <a href="#S14.3">14.3</a>).</span> </p>
<p class="Highlighta"><span class="Bold">MULTAQ is contraindicated in patients in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (AF) who will not or cannot be cardioverted into normal sinus rhythm. In patients with permanent AF, MULTAQ doubles the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#S4">4</a>, <a href="#S5.2">5.2</a>,<a href="#S14.4">14.4</a>)</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">MULTAQ is an antiarrhythmic drug indicated to reduce the risk of hospitalization for <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF (<a href="#S1">1</a>, <a href="#S14">14</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">One tablet of 400 mg twice a day with morning and evening meals (<a href="#S2">2</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">400 mg film-coated tablets (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Permanent AF (patients in whom normal sinus rhythm will not or cannot be restored)  (<a href="#box">Boxed Warning</a>, <a href="#S4">4</a>)</li>
<li>Recently <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">decompensated heart failure</span> requiring hospitalization or Class IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#box">Boxed Warning</a>, <a href="#S4">4</a>)</li>
<li>Second- or third- degree atrioventicular (AV) block or <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span> (except when used in conjunction with a functioning pacemaker) (<a href="#S4">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> &lt;50 bpm (<a href="#S4">4</a>) </li>
<li>Concomitant use of a strong CYP3A inhibitor (<a href="#S4">4</a>)</li>
<li>Concomitant use of drugs or herbal products that prolong the QT interval and may induce <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> (<a href="#S4">4</a>)</li>
<li>Liver toxicity related to the previous use of amiodarone (<a href="#S4">4</a>)</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="#S4">4</a>)</li>
<li>QTc Bazett interval ≥500 ms (<a href="#S4">4</a>)</li>
<li>Pregnancy (<a href="#S4">4</a>, <a href="#S8.1">8.1</a>) and Nursing mothers (<a href="#S4">4</a>, <a href="#S8.3">8.3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Determine cardiac rhythm at least once every 3 months. If AF is detected discontinue MULTAQ or cardiovert (<a href="#S5.2">5.2</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver injury</span>: if hepatic injury is suspected, discontinue MULTAQ (<a href="#S5.5">5.5</a>)</li>
<li>Ensure appropriate antithrombotic therapy prior to and throughout MULTAQ use. (<a href="#S5.3">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>: Maintain potassium and magnesium levels within the normal range (<a href="#S5.6">5.6</a>)</li>
<li>Increase in creatinine: Monitor serum creatinine periodically (<a href="#S5.8">5.8</a>)</li>
<li>
<a href="#S5">5</a>)</li>
<li>Teratogen: Women of childbearing potential should use effective contraception while using MULTAQ (<a href="#S5.9">5.9</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥2%) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (<a href="#S6">6</a>) </p>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis U.S. LLC at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">Dronedarone is metabolized by CYP 3A and is a moderate inhibitor of  </p>
<p class="Highlighta">CYP 3A and CYP 2D6 and has potentially important <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span> (<a href="#S7">7</a>) </p>
<ul class="Disc">
<li>Antiarrhythmics: Avoid concomitant use (<a href="#S4">4</a>, <a href="#S7.1">7.1</a>)</li>
<li>Digoxin: Consider discontinuation or halve dose of digoxin before treatment and monitor digoxin levels (<a href="#S7.1">7.1</a>, <a href="#S7.3">7.3</a>)</li>
<li>Calcium channel blockers (CCB): Initiate CCB with low dose and increase after ECG verification of tolerability (<a href="#S7.1">7.1</a>,<a href="#S7.2">7.2</a>, <a href="#S7.3">7.3</a>)</li>
<li>Beta-blockers: May provoke excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, Initiate with low dose and increase after ECG verification of tolerability (<a href="#S7.1">7.1</a>, <a href="#S7.3">7.3</a>)</li>
<li>CYP 3A inducers: Avoid concomitant use (<a href="#S7.2">7.2</a>)</li>
<li>Grapefruit juice: Avoid concomitant use (<a href="#S7.2">7.2</a>)</li>
<li>Statins: Follow label recommendations for concomitant use of certain statins with a CYP 3A and P-gP inhibitor like dronedarone (<a href="#S7.3">7.3</a>)</li>
<li>CYP 3A substrates with a narrow therapeutic index (e.g., sirolimus and tacrolimus): Monitor and adjust dosage of concomitant drug as needed when used with MULTAQ (<a href="#S7.3">7.3</a>)</li>
<li>Warfarin: Monitor INR after initiating dronedarone in patients taking warfarin. (<a href="#S7.3">7.3</a>)</li>
</ul>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 12/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: INCREASED RISK OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">STROKE</span> AND <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span> IN PATIENTS WITH <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">DECOMPENSATED HEART FAILURE</span> OR PERMANENT <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">ATRIAL FIBRILLATION</span></span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> in NYHA Class IV or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Decompensated Heart Failure</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> in Permanent AF</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Increased Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in Permanent AF</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 New Onset or Worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> with Potassium-Depleting Diuretics</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 QT Interval Prolongation</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Increase in Creatinine after Treatment Initiation</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Women of Childbearing Potential</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacodynamic Interactions</span></a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Effects of Other Drugs on Dronedarone</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Effects of Dronedarone on Other Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.3	Developmental Toxicity</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 ATHENA</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 EURIDIS and ADONIS</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 ANDROMEDA</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 PALLAS </a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Information for Patients</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: INCREASED RISK OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">STROKE</span> AND <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span> IN PATIENTS WITH <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">DECOMPENSATED HEART FAILURE</span> OR PERMANENT <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">ATRIAL FIBRILLATION</span></span></h1>
<p class="First"><span class="Bold">In patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and recent decompensation requiring hospitalization or NYHA Class IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>; MULTAQ doubles the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. (<a href="#S14.3">14.3</a>) MULTAQ is contraindicated in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with recent decompensation requiring hospitalization or NYHA Class IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#S4">4</a>, <a href="#S5.1">5.1</a>)</span></p>
<p><span class="Bold">In patients with permanent <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, MULTAQ doubles the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#S14.4">14.4</a>). MULTAQ is contraindicated in patients in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (AF) who will not or cannot be cardioverted into normal sinus rhythm.  (<a href="#S4">4</a>, <a href="#S5.2">5.2</a>)</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">MULTAQ<span class="Sup">®</span> is indicated to reduce the risk of hospitalization for <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> in patients in sinus rhythm with a history of paroxysmal or persistent <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (AF) <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dosage of MULTAQ is 400 mg twice daily in adults. MULTAQ should be taken as one tablet with the morning meal and one tablet with the evening meal.</p>
<p>Treatment with Class I or III antiarrhythmics (e.g., amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol) or drugs that are strong inhibitors of CYP3A (e.g., ketoconazole) must be stopped before starting MULTAQ <span class="Italics">[see <a href="#S4">Contraindications (4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">MULTAQ 400 mg tablets are provided as white film-coated tablets for oral administration, oblong-shaped, engraved with a double wave marking on one side and "4142" code on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">MULTAQ is contraindicated in patients with:</p>
<ul class="Disc">
<li style="border-left:1px solid;"><span class="XmChange">Permanent <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (patients in whom normal sinus rhythm will not or cannot be restored) <span class="Italics">[see <a href="#box">Boxed Warning</a> and <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span></span></li>
<li style="border-left:1px solid;"><span class="XmChange">Symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with recent decompensation requiring hospitalization or NYHA Class IV symptoms <span class="Italics">[see <a href="#box">Boxed Warning</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span></span></li>
<li>Second- or third-degree atrioventricular (AV) block, or <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span> (except when used in conjunction with a functioning pacemaker)</li>
<li><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> &lt;50 bpm </li>
<li>Concomitant use of strong CYP 3A inhibitors, such as ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, and ritonavir <span class="Italics">[see <a href="#S7.2">Drug Interactions (7.2)</a>]</span>
</li>
<li>Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>, such as phenothiazine anti-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotics</span>, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics  </li>
<li style="border-left:1px solid;"><span class="XmChange">Liver toxicity related to the previous use of amiodarone</span></li>
<li>QTc Bazett interval ≥500 ms or PR interval &gt;280 ms</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span></li>
<li>Pregnancy (Category X): MULTAQ may cause fetal harm when administered to a pregnant woman. MULTAQ is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</li>
<li>Nursing mothers <span class="Italics">[see <a href="#S8.3">Use in Specific Populations (8.3)</a>]</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> in NYHA Class IV or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Decompensated Heart Failure</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">MULTAQ is contraindicated in patients with NYHA Class IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with recent decompensation requiring hospitalization because it doubles the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> in Permanent AF</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">MULTAQ doubles the risk of cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (largely arrhythmic) and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> events in patients with permanent AF. Patients treated with dronedarone should undergo monitoring of cardiac rhythm no less often than every 3 months. Cardiovert patients who are in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (if clinically indicated) or discontinue MULTAQ. MULTAQ offers no benefit in subjects in permanent AF.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Increased Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in Permanent AF</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In a placebo-controlled study in patients with permanent <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, dronedarone was associated with an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, particularly in the first two weeks of therapy [<span class="Italics"><a href="#S14.4">see Clinical Studies (14.4)</a></span>]. MULTAQ should only be initiated in patients in sinus rhythm who are receiving appropriate antithrombotic therapy [<span class="Italics">see <a href="#S7.3">Drug interactions (7.3)</a></span>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 New Onset or Worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">New onset or worsening of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> has been reported during treatment with MULTAQ in the postmarketing setting. In a placebo controlled study in patients with permanent AF increased rates of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> were observed in patients with normal left ventricular function and no history of symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, as well as those with a history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>. </span></p>
<p>Advise patients to consult a physician if they develop signs or symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, such as <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">dependent edema</span>, or increasing <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>. If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> develops or worsens and requires hospitalization, discontinue MULTAQ. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Hepatocellular <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> requiring transplant, has been reported in patients treated with MULTAQ in the post-marketing setting. Advise patients treated with MULTAQ to report immediately symptoms suggesting hepatic injury (such as <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">right upper quadrant pain</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, dark urine, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>). Consider obtaining periodic hepatic serum enzymes, especially during the first 6 months of treatment, but it is not known whether routine periodic monitoring of serum enzymes will prevent the development of severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. If hepatic injury is suspected, promptly discontinue MULTAQ and test serum enzymes, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST), <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) and alkaline phosphatase, as well as serum bilirubin, to establish whether there is <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. If <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is found, institute appropriate treatment and investigate the probable cause. Do not restart MULTAQ in patients without another explanation for the observed <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> with Potassium-Depleting Diuretics</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> may occur with concomitant administration of potassium-depleting diuretics. Potassium levels should be within the normal range prior to administration of MULTAQ and maintained in the normal range during administration of MULTAQ.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 QT Interval Prolongation</h2>
<p class="First">Dronedarone induces a moderate (average of about 10 ms but much greater effects have been observed) QTc (Bazett) prolongation <span class="Italics">[see <a href="#S12.2">Clinical Pharmacology (12.2)</a> and <a href="#S14.1">Clinical Studies (14.1)</a>]</span>. If the QTc Bazett interval is ≥500 ms, discontinue MULTAQ <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Increase in Creatinine after Treatment Initiation</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Small increases in creatinine levels (about 0.1 mg/dL) following dronedarone treatment initiation have been shown to be a result of inhibition of creatinine's tubular secretion. ..</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The elevation has a rapid onset, reaches a plateau after 7 days and is reversible after discontinuation. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Larger increases in creatinine after dronedarone initiation have been reported in the postmarketing setting. Some cases also reported increases in blood urea nitrogen. In most cases, these effects appear to be reversible upon drug discontinuation. Monitor renal function periodically.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Women of Childbearing Potential</h2>
<p class="First">Premenopausal women who have not undergone a hysterectomy or oophorectomy must use effective contraception while using MULTAQ. Dronedarone caused fetal harm in animal studies at doses equivalent to recommended human doses. Counsel women of childbearing potential regarding appropriate contraceptive choices.  <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following safety concerns are described elsewhere in the label:</p>
<ul class="Disc">
<li>New or worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span> <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> with potassium-depleting diuretics <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>
</li>
<li>QT prolongation <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">The safety evaluation of dronedarone 400 mg twice daily in patients with AF or AFL is based on 5 placebo controlled studies, ATHENA, EURIDIS, ADONIS, ERATO and DAFNE. In these studies, a total of 6285 patients were randomized and treated, 3282 patients with MULTAQ 400 mg twice daily, and 2875 with placebo. The mean exposure across studies was 12 months. In ATHENA, the maximum follow-up was 30 months.</p>
<p>In clinical trials, premature discontinuation because of adverse reactions occurred in 11.8% of the dronedarone-treated patients and in 7.7% of the placebo-treated group. The most common reasons for discontinuation of therapy with MULTAQ were <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> (3.2 % versus 1.8% in the placebo group) and QT prolongation (1.5% versus 0.5% in the placebo group).</p>
<p>The most frequent adverse reactions observed with MULTAQ 400 mg twice daily in the 5 studies were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>.</p>
<p>Table 1 displays adverse reactions more common with dronedarone 400 mg twice daily than with placebo in AF or AFL patients, presented by system organ class and by decreasing order of frequency. Adverse laboratory and ECG effects are presented separately in Table 2. </p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1: Adverse Drug Reactions that Occurred in at Least 1% of Patients and Were More Frequent than Placebo</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2"></th>
<th class="Rrule" align="center">Placebo</th>
<th class="Rrule" align="center">Dronedarone 400 mg twice daily</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">(N=2875)</th>
<th class="Rrule" align="center">(N=3282)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Underline">Gastrointestinal</span></span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td class="Rrule" align="center">6%</td>
<td class="Rrule" align="center">9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Dyspeptic signs and symptoms</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Underline">General </span></span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Asthenic conditions</td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Underline">Cardiac</span></span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Underline">Skin and subcutaneous tissue </span></span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> (generalized, macular, maculo-papular, erythematous), <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">dermatitis allergic</span></td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">5%</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity reaction</span> and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span> have also been reported at an incidence less than 1% in patients treated with MULTAQ.</p>
<p>The following laboratory data/ECG parameters were reported with MULTAQ 400 mg twice daily.</p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2: Laboratory data/ECG parameters not necessarily reported as adverse events</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Placebo</th>
<th class="Rrule" align="center">MULTAQ<br>400 mg twice daily</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="center"><span class="Bold">(N=2875)</span></td>
<td class="Rrule" align="center"><span class="Bold">(N=3282)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Early increases in creatinine ≥10%</td>
<td class="Rrule" align="center">21%</td>
<td class="Rrule" align="center">51%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="center"><span class="Bold">(N=2237) </span></td>
<td class="Rrule" align="center"><span class="Bold">(N=2701)</span></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">QTc prolonged </td>
<td class="Rrule" align="center">19%</td>
<td class="Rrule" align="center">28%</td>
</tr>
</tbody>
</table>
<p>Assessment of demographic factors such as gender or age on the incidence of treatment-emergent adverse events did not suggest an excess of adverse events in any particular sub-group.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of MULTAQ. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Bold">Cardiac:</span> New or worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Bold">Hepatic:</span> <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span> <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.3"></a><p></p>
<p class="First"><span class="Bold">Respiratory:</span> Postmarketing cases of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span> have been reported.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Dronedarone is metabolized primarily by CYP 3A and is a moderate inhibitor of CYP 3A and CYP 2D6 <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. Dronedarone's blood levels can therefore be affected by inhibitors and inducers of CYP 3A, and dronedarone can interact with drugs that are substrates of CYP 3A and CYP 2D6.</p>
<p>Dronedarone has no significant potential to inhibit CYP 1A2, CYP 2C9, CYP 2C19, CYP 2C8 and CYP 2B6. It has the potential to inhibit P-glycoprotein (P-gP) transport.</p>
<p><span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacodynamic interactions</span> can be expected with beta-blockers; calcium antagonists and digoxin <span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a>]</span>. </p>
<p>In clinical trials, patients treated with dronedarone received concomitant medications including beta-blockers, digoxin, calcium antagonists (including those with heart rate-lowering effects), statins and oral anticoagulants. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacodynamic Interactions</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<p class="First">Drugs prolonging the QT interval (inducing <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>) </p>
<p>Co-administration of drugs prolonging the QT interval (such as certain phenothiazines, tricyclic antidepressants, certain macrolide antibiotics, and Class I and III antiarrhythmics) is contraindicated because of the potential risk of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>-type <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.2"></a><p></p>
<p class="First">Digoxin</p>
<p>Digoxin can potentiate the electrophysiologic effects of dronedarone (such as decreased AV-node conduction). In clinical trials, increased levels of digoxin were observed when dronedarone was co-administered with digoxin. <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span> were also increased.</p>
<p>Because of the <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> <span class="Italics">[see <a href="#S7.3">Drug Interaction (7.3)</a>]</span> and possible <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span>, consider the need for continued digoxin therapy. If digoxin treatment is continued, halve the dose of digoxin, monitor serum levels closely, and observe for toxicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.3"></a><p></p>
<p class="First">Calcium channel blockers</p>
<p>Calcium channel blockers with depressant effects on the sinus and AV nodes could potentiate dronedarone's effects on conduction.</p>
<p>Give low doses of calcium channel blockers initially and increase only after ECG verification of good tolerability <span class="Italics">[see <a href="#S7.3">Drug Interactions (7.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.4"></a><p></p>
<p class="First">Beta-blockers </p>
<p>In clinical trials, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> was more frequently observed when dronedarone was given in combination with beta-blockers.</p>
<p>Give low dose of beta-blockers initially, and increase only after ECG verification of good tolerability <span class="Italics">[see <a href="#S7.3">Drug Interactions (7.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Effects of Other Drugs on Dronedarone</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<p class="First">Ketoconazole and other potent CYP 3A inhibitors</p>
<p>Repeated doses of ketoconazole, a strong CYP 3A inhibitor, resulted in a 17-fold increase in dronedarone exposure and a 9-fold increase in C<span class="Sub">max</span>. Concomitant use of ketoconazole as well as other potent CYP 3A inhibitors such as itraconazole, voriconazole, ritonavir, clarithromycin, and nefazodone is contraindicated <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.2"></a><p></p>
<p class="First">Grapefruit juice</p>
<p>Grapefruit juice, a moderate inhibitor of CYP 3A, resulted in a 3-fold increase in dronedarone exposure and a 2.5-fold increase in C<span class="Sub">max</span>. Therefore, patients should avoid grapefruit juice beverages while taking MULTAQ.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.3"></a><p></p>
<p class="First">Rifampin and other CYP 3A inducers</p>
<p>Rifampin decreased dronedarone exposure by 80%. Avoid rifampin or other CYP 3A inducers such as phenobarbital, carbamazepine, phenytoin, and St John's wort with dronedarone because they decrease its exposure significantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.4"></a><p></p>
<p class="First">Calcium channel blockers</p>
<p>Verapamil and diltiazem are moderate CYP 3A inhibitors and increase dronedarone exposure by approximately 1.4-to 1.7-fold <span class="Italics">[see<a href="#S7.1"> Drug Interactions (7.1</a>, <a href="#S7.3">7.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.5"></a><p></p>
<p class="First">Pantoprazole</p>
<p>Pantoprazole, a drug that increases gastric pH, did not have a significant effect on dronedarone pharmacokinetics. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Effects of Dronedarone on Other Drugs</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<p class="First">Statins </p>
<p>Dronedarone increased simvastatin/simvastatin acid exposure by 4- and 2-fold, respectively. Because of multiple mechanisms of interaction with statins (CYPs and transporters), follow statin label recommendations for use with CYP 3A and P-gP inhibitors such as dronedarone. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.2"></a><p></p>
<p class="First">Calcium channel blockers</p>
<p>Dronedarone increases calcium channel blocker (verapamil, diltiazem or nifedipine) exposure by 1.4- to 1.5-fold <span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.3"></a><p></p>
<p class="First">Sirolimus, tacrolimus, and other CYP3A substrates with narrow therapeutic range </p>
<p>Dronedarone can increase plasma concentrations of tacrolimus, sirolimus, and other CYP 3A substrates with a narrow therapeutic range when given orally. Monitor plasma concentrations and adjust dosage appropriately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.4"></a><p></p>
<p class="First">Beta-blockers and other CYP 2D6 substrates</p>
<p>Dronedarone increased propranolol exposure by approximately 1.3-fold following single dose administration. Dronedarone increased metoprolol exposure by 1.6-fold following multiple dose administration <span class="Italics">[see <a href="#S7.1">Drug Interaction (7.1)</a>]. </span>Other CYP 2D6 substrates, including other beta-blockers, tricyclic antidepressants, and selective serotonin reuptake inhibitors (SSRIs) may have increased exposure upon co-administration with dronedarone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.5"></a><p></p>
<p class="First">P-glycoprotein substrates</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.5.1"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics">Digoxin</span></p>
<p>Dronedarone increased digoxin exposure by 2.5-fold by inhibiting the P-gP transporter [<span class="Italics">see <a href="#S7.1">Drug Interactions (7.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.5.2"></a><p></p>
<h4></h4>
<p class="First"><span class="Italics">Dabigatran</span></p>
<p>Exposure to dabigatran is higher when it is administered with dronedarone than when it is administered alone (1.7- to 2-fold).</p>
<p>Other P-gP substrates are expected to have increased exposure when co-administered with dronedarone.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.6"></a><p></p>
<p class="First">Warfarin and losartan (CYP 2C9 substrates)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.6.1"></a><p></p>
<p class="First"><span class="Italics">Losartan</span></p>
<p>No interaction was observed between dronedarone and losartan.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.6.2"></a><p></p>
<p class="First"><span class="Italics">Warfarin</span></p>
<p>When healthy subjects were administered dronedarone 600 mg twice daily, exposure to S-warfarin was higher than when warfarin was administered alone (1.2-fold). Exposure to R-warfarin was unchanged and there were no clinically significant increases in INR.</p>
<p>More patients experienced clinically significant INR elevations (≥ 5) usually within 1 week after starting dronedarone vs. placebo in patients taking oral anticoagulants in ATHENA. However, no excess risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> was observed in the dronedarone group.</p>
<p>Postmarketing cases of increased INR with or without <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events have been reported in warfarin-treated patients initiated on dronedarone. Monitor INR after initiating dronedarone in patients taking warfarin.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.7"></a><p></p>
<p class="First">Theophylline (CYP 1A2 substrate)</p>
<p>Dronedarone does not increase steady state theophylline exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.8"></a><p></p>
<p class="First">Oral contraceptives</p>
<p>No decreases in ethinylestradiol and levonorgestrel concentrations were observed in healthy subjects receiving dronedarone concomitantly with oral contraceptives.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category X <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span></p>
<p>MULTAQ may cause fetal harm when administered to a pregnant woman. In animal studies, dronedarone was teratogenic in rats at the maximum recommended human dose (MRHD), and in rabbits at half the MRHD. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. </p>
<p>When pregnant rats received dronedarone at oral doses greater than or equal to the MRHD (on a mg/m<span class="Sup">2</span> basis), fetuses had increased rates of external, visceral and skeletal malformations (cranioschisis, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, incomplete evagination of pineal body, brachygnathia, partially fused carotid arteries, truncus arteriosus, abnormal lobation of the liver, partially duplicated inferior vena cava, brachydactyly, ectrodactylia, syndactylia, and anterior and/or posterior club feet). When pregnant rabbits received dronedarone, at a dose approximately half the MRHD (on a mg/m<span class="Sup">2 </span>basis), fetuses had an increased rate of skeletal abnormalities (anomalous ribcage and vertebrae, pelvic asymmetry) at doses ≥20 mg/kg (the lowest dose tested and approximately half the MRHD on a mg/m<span class="Sup">2</span> basis).</p>
<p>Actual animal doses: rat (≥80 mg/kg/day); rabbit (≥20 mg/kg)</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether MULTAQ is excreted in human milk. Dronedarone and its metabolites are excreted in rat milk. During a pre- and post-natal study in rats, maternal dronedarone administration was associated with minor reduced body-<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in the offspring. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from MULTAQ, discontinue nursing or discontinue the drug <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy in children below the age of 18 years have not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">More than 4500 patients with AF or AFL aged 65 years or above were included in the MULTAQ clinical program (of whom more than 2000 patients were 75 years or older). Efficacy and safety were similar in elderly and younger patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> were included in clinical studies. Because renal excretion of dronedarone is minimal <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>, no dosing alteration is needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Dronedarone is extensively metabolized by the liver. There is little clinical experience with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and none with severe impairment. No dosage adjustment is recommended for moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In the event of overdosage, monitor the patient's cardiac rhythm and blood pressure. Treatment should be supportive and based on symptoms.</p>
<p>It is not known whether dronedarone or its metabolites can be removed by dialysis (hemodialysis, peritoneal dialysis or hemofiltration). </p>
<p>There is no specific antidote available.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Dronedarone HCl is a benzofuran derivative with the following chemical name:</p>
<p>N-{2-butyl-3-[4-(3-dibutylaminopropoxy)benzoyl]benzofuran-5-yl} methanesulfonamide, hydrochloride. </p>
<p>Dronedarone HCl is a white fine powder that is practically insoluble in water and freely soluble in methylene chloride and methanol. </p>
<p>Its empirical formula is C<span class="Sub">31</span>H<span class="Sub">44</span>N<span class="Sub">2</span>O<span class="Sub">5 </span>S, HCl with a relative molecular <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> of 593.2. Its structural formula is: </p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=236d4549-f44b-4677-b857-acedd10b9920&amp;name=multaq-01.jpg"></p>
<p>MULTAQ is provided as tablets for oral administration.</p>
<p>Each tablet of MULTAQ contains 400 mg of dronedarone (expressed as base). </p>
<p>The inactive ingredients are:</p>
<dl>
<dt> </dt>
<dd>Core of the tablets- hypromellose, starch, crospovidone, poloxamer 407, lactose monohydrate, colloidal silicon dioxide, magnesium stearate. </dd>
<dt> </dt>
<dd>Coating / polishing of the tablets- hypromellose, polyethylene glycol 6000, titanium dioxide, carnauba wax.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of dronedarone is unknown. Dronedarone has antiarrhythmic properties belonging to all four Vaughan-Williams classes, but the contribution of each of these activities to the clinical effect is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First">Electrophysiological effects</p>
<p>Dronedarone exhibits properties of all four Vaughn-Williams antiarrhythmic classes, although it is unclear which of these are important in producing dronedarone's clinical effects. The effect of dronedarone on 12-lead ECG parameters (heart rate, PR, and QTc) was investigated in healthy subjects following repeated oral doses up to 1600 mg once daily or 800 mg twice daily for 14 days and 1600 mg twice daily for 10 days. In the dronedarone 400 mg twice daily group, there was no apparent effect on heart rate; a moderate heart rate lowering effect (about 4 bpm) was noted at 800 mg twice daily. There was a clear dose-dependent effect on PR-interval with an increase of +5 ms at 400 mg twice daily and up to +50 ms at 1600 mg twice daily. There was a moderate dose related effect on the QTc-interval with an increase of +10 ms at 400 mg twice daily and up to +25 ms with 1600 mg twice daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First">DAFNE study</p>
<p>DAFNE was a dose-response study in patients with recurrent AF, evaluating the effect of dronedarone in comparison with placebo in maintaining sinus rhythm. The doses of dronedarone in this study were 400, 600, and 800 mg twice a day. In this small study, doses above 400 mg were not more effective and were less well tolerated.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Dronedarone is extensively metabolized and has low systemic bioavailability; its bioavailability is increased by meals. Its elimination half life is 13–19 hours.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First">Absorption</p>
<p>Because of presystemic first pass metabolism the absolute bioavailability of dronedarone without food is low, about 4%. It increases to approximately 15% when dronedarone is administered with a high fat meal. After oral administration in fed conditions, peak plasma concentrations of dronedarone and the main circulating active metabolite (N-debutyl metabolite) are reached within 3 to 6 hours. After repeated administration of 400 mg twice daily, steady state is reached within 4 to 8 days of treatment and the mean accumulation ratio for dronedarone ranges from 2.6 to 4.5. The steady state C<span class="Sub">max</span> and exposure of the main N-debutyl metabolite is similar to that of the parent compound. The pharmacokinetics of dronedarone and its N-debutyl metabolite both deviate moderately from dose proportionality: a 2-fold increase in dose results in an approximate 2.5- to 3.0- fold increase with respect to C<span class="Sub">max </span>and AUC.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First">Distribution</p>
<p>The<span class="Italics"> in vitro</span> plasma protein binding of dronedarone and its N-debutyl metabolite is &gt;98 % and not saturable. Both compounds bind mainly to albumin. After intravenous (IV) administration the volume of distribution at steady state is about 1400 L. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First">Metabolism</p>
<p>Dronedarone is extensively metabolized, mainly by CYP 3A. The initial metabolic pathway includes N-debutylation to form the active N-debutyl metabolite, oxidative deamination to form the inactive propanoic acid metabolite, and direct oxidation. The metabolites undergo further metabolism to yield over 30 uncharacterized metabolites. The N-debutyl metabolite exhibits pharmacodynamic activity but is 1/10 to 1/3 as potent as dronedarone </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First">Excretion/Elimination</p>
<p>In a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study with orally administered dronedarone (<span class="Sup">14</span>C-labeled) approximately 6% of the labeled dose was excreted in urine, mainly as metabolites (no unchanged compound excreted in urine), and 84% was excreted in feces, mainly as metabolites. Dronedarone and its N-debutyl active metabolite accounted for less than 15% of the resultant radioactivity in the plasma.</p>
<p>After IV administration the plasma clearance of dronedarone ranges from 130 to 150 L/h. The elimination half-life of dronedarone ranges from 13 to 19 hours. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First">Special populations</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Italics">Gender</span></p>
<p>Dronedarone exposures are on average 30% higher in females than in males.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Italics">Race</span></p>
<p>Pharmacokinetic differences related to race were not formally assessed. However, based on a cross study comparison, following single dose administration (400 mg), Asian males (Japanese) have about a 2-fold higher exposure than Caucasian males. The pharmacokinetics of dronedarone in other races has not been assessed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.3"></a><p></p>
<p class="First"><span class="Italics">Elderly </span></p>
<p>Of the total number of subjects in clinical studies of dronedarone, 73% were 65 years of age and over and 34% were 75 and over. In patients aged 65 years old and above, dronedarone exposures are 23% higher than in patients less than 65 years old <span class="Italics">[see <a href="#S8.5">Use in Specific Populations (8.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span></span></p>
<p>In subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the mean dronedarone exposure increased by 1.3-fold relative to subjects with normal hepatic function and the mean exposure of the N-debutyl metabolite decreased by about 50%. Pharmacokinetic data were significantly more variable in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>The effect of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of dronedarone was not assessed<span class="Italics"> [see <a href="#S4">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.5"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span></span></p>
<p>Consistent with the low renal excretion of dronedarone, no pharmacokinetic difference was observed in subjects with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared to subjects with normal renal function <span class="Italics">[see <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>. No pharmacokinetic difference was observed in patients with mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> in comparison with patients with normal renal function.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In studies in which dronedarone was administered to rats and mice for up to 2 years at doses of up to 70 mg/kg/day and 300 mg/kg/day, respectively, there was an increased incidence of histiocytic <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span> in dronedarone-treated male mice (300 mg/kg/day or 5× the maximum recommended human dose based on AUC comparisons), mammary adenocarcinomas in dronedarone-treated female mice (300 mg/kg/day or 8× MRHD based on AUC comparisons) and <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> in dronedarone-treated male rats (70 mg/kg/day or 5× MRHD based on AUC comparisons).</p>
<p>Dronedarone did not demonstrate genotoxic potential in the in vivo mouse micronucleus test, the Ames bacterial mutation assay, the unscheduled DNA synthesis assay, or an in vitro chromosomal aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. S-9 processed dronedarone, however, was positive in a V79 transfected Chinese hamster V79 assay. </p>
<p>In fertility studies conducted with female rats, dronedarone given prior to breeding and implantation caused an increase in irregular estrus cycles and cessation of cycling at doses ≥10mg/kg (equivalent to 0.12× the MRHD on a mg/m<span class="Sup">2</span> basis).</p>
<p>Corpora lutea, implantations and live fetuses were decreased at 100 mg/kg (equivalent to 1.2× the MRHD on a mg/m<span class="Sup">2</span> basis). There were no reported effects on mating behavior or fertility of male rats at doses of up to 100 mg/kg/day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S13.3"></a><a name="section-12.2"></a><p></p>
<h2>13.3	Developmental Toxicity</h2>
<p class="First">Dronedarone was teratogenic in rats given oral doses ≥80 mg/kg/day (a dose equivalent to the maximum recommended human dose [MHRD] on a mg/m<span class="Sup">2</span> basis), with fetuses showing external, visceral and skeletal malformations (cranioschisis, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, incomplete evagination of pineal body, brachygnathia, partially fused carotid arteries, truncus arteriosus, abnormal lobation of the liver, partially duplicated inferior vena cava, brachydactyly, ectrodactylia, syndactylia, and anterior and/or posterior club feet). In rabbits, dronedarone caused an increase in skeletal abnormalities (anomalous ribcage and vertebrae, pelvic asymmetry) at doses ≥20 mg/kg (the lowest dose tested and approximately half the MRHD on a mg/m<span class="Sup">2</span> basis). </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 ATHENA</h2>
<p class="First">ATHENA was a multicenter, multinational, double blind, and randomized placebo-controlled study of dronedarone in 4628 patients with a recent history of AF/AFL who were in sinus rhythm or who were to be converted to sinus rhythm. The objective of the study was to determine whether dronedarone could delay <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause or hospitalization for cardiovascular reasons.</p>
<p>Initially patients were to be ≥70 years old, or &lt;70 years old with at least one risk factor (including <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, prior <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, left atrial diameter ≥50 mm or LVEF&lt;0.40). The inclusion criteria were later changed such that patients were to be ≥75 years old, or ≥70 years old with at least one risk factor. Patients had to have both AF/AFL and sinus rhythm documented within the previous 6 months. Patients could have been in AF/AFL or in sinus rhythm at the time of randomization, but patients not in sinus rhythm were expected to be either electrically or chemically converted to normal sinus rhythm after anticoagulation. </p>
<p>Subjects were randomized and treated for up to 30 months (median follow-up: 22 months) with either MULTAQ 400 mg twice daily (2301 patients) or placebo (2327 patients), in addition to conventional therapy for cardiovascular diseases that included beta-blockers (71%), ACE inhibitors or angiotensin II receptor blockers (ARBs)(69%), digoxin (14%), calcium antagonists (14%), statins (39%), oral anticoagulants (60%), aspirin (44%), other chronic antiplatelet therapy (6%) and diuretics (54%). </p>
<p>The primary endpoint of the study was the time to first hospitalization for cardiovascular reasons or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause. Time to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause, time to first hospitalization for cardiovascular reasons, and time to cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and time to all causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were also explored.</p>
<p>Patients ranged in age from 23 to 97 years; 42% were 75 years old or older. Forty-seven percent (47%) of patients were female and a majority was Caucasian (89%). Approximately seventy percent (71%) of those enrolled had no history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. The median <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> was 60%. Twenty-nine percent (29%) of patients had <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, mostly NYHA class II (17%). The majority had <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (86%) and structural heart disease (60%).</p>
<p>Results are shown in Table 3. MULTAQ reduced the combined endpoint of cardiovascular hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause by 24.2% when compared to placebo. This difference was entirely attributable to its effect on cardiovascular hospitalization, principally hospitalization related to AF.</p>
<p>Other endpoints, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause and first hospitalization for cardiovascular reasons, are shown in Table 3. Secondary endpoints count all first events of a particular type, whether or not they were preceded by a different type of event.</p>
<a name="table3"></a><table width="100%">
<caption><span>Table 3: Incidence of Endpoint Events</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Placebo</th>
<th class="Rrule" align="center">MULTAQ<br>400mg BID</th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">(N= 2327)</th>
<th class="Rrule" align="center">(N= 2301)</th>
<th class="Rrule" align="center">HR</th>
<th class="Rrule" align="center">95% CI</th>
<th class="Rrule" align="center">p-Value</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Primary endpoint</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">											Cardiovascular hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause</td>
<td class="Rrule" align="center">913 (39.2%)</td>
<td class="Rrule" align="center">727 (31.6%)</td>
<td class="Rrule" align="center">0.76</td>
<td class="Rrule" align="center">[0.68 – 0.83]</td>
<td class="Rrule" align="center">&lt;0.0001</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="6"> </td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Components of the endpoint (as first event)</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><ul><li>Cardiovascular hospitalization</li></ul></td>
<td class="Rrule" align="center">856 (36.8%)</td>
<td class="Rrule" align="center">669 (29.1%)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><ul><li><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> from any cause</li></ul></td>
<td class="Rrule" align="center">57 (2.4%)</td>
<td class="Rrule" align="center">58 (2.5%)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="6"> </td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Secondary endpoints (any time in study) 												</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><ul><li><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> from any cause</li></ul></td>
<td class="Rrule" align="center">135 (5.8%)</td>
<td class="Rrule" align="center">115 (5.0%)</td>
<td class="Rrule" align="center">0.86</td>
<td class="Rrule" align="center">[0.67 – 1.11]</td>
<td class="Rrule" align="center">0.24</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><ul><li>Cardiovascular hospitalization</li></ul></td>
<td class="Rrule" align="center">856 (36.8%)</td>
<td class="Rrule" align="center">669 (29.1%)</td>
<td class="Rrule" align="center">0.74</td>
<td class="Rrule" align="center">[0.67 – 0.82]</td>
<td class="Rrule" align="center">&lt;0.0001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Components of the cardiovascular hospitalization endpoint (as first event)</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><ul class="Disc"><li>AF and other supraventricular rhythm disorders</li></ul></td>
<td class="Rrule" align="center">456 (19.6%)</td>
<td class="Rrule" align="center">292 (12.7%)</td>
<td class="Rrule" align="center">0.61<br>
</td>
<td class="Rrule" align="center">[0.53 – 0.71]</td>
<td class="Rrule" align="center">&lt;0.0001</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><ul class="Disc"><li>Other</li></ul></td>
<td class="Rrule" align="center">400 (17.2%)</td>
<td class="Rrule" align="center">377 (16.4%)</td>
<td class="Rrule" align="center">0.89</td>
<td class="Rrule" align="center">[0.77 – 1.03]</td>
<td class="Rrule" align="center">0.11</td>
</tr>
</tbody>
</table>
<p>The Kaplan-Meier cumulative incidence curves showing the time to first event are displayed in Figure 1. The event curves separated early and continued to diverge over the 30 month follow-up period.</p>
<p><span class="Bold Underline">Figure 1:</span><span class="Bold"> Kaplan-Meier Cumulative Incidence Curves from Randomization to First Cardiovascular Hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> from any Cause</span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=236d4549-f44b-4677-b857-acedd10b9920&amp;name=multaq-02.jpg"></div>
<p>Reasons for hospitalization included major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (1% in both groups), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (1% in both groups), and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> (&lt;1% in both groups).</p>
<p>The reduction in cardiovascular hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause was generally consistent in all subgroups based on baseline characteristics or medications (ACE inhibitors or ARBs; beta-blockers, digoxin, statins, calcium channel blockers, diuretics) (see <a href="#figure2">Figure 2</a>). </p>
<p><span class="Bold Underline">Figure 2:</span><span class="Bold"> Relative Risk (MULTAQ versus placebo) Estimates with 95% Confidence Intervals According to Selected Baseline Characteristics: First Cardiovascular Hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> from any Cause. </span></p>
<p><a name="figure2"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=236d4549-f44b-4677-b857-acedd10b9920&amp;name=multaq-03.jpg"></p>
<p>a Determined from Cox regression model<br>b P-value of interaction between baseline characteristics and treatment based on Cox regression model<br>c Calcium antagonists with heart rate lowering effects restricted to diltiazem, verapamil and bepridil</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 EURIDIS and ADONIS</h2>
<p class="First">In EURIDIS and ADONIS, a total of 1237 patients in sinus rhythm with a prior episode of AF or AFL were randomized in an outpatient setting and treated with either MULTAQ 400 mg twice daily (n=828) or placebo (n=409) on top of conventional therapies (including oral anticoagulants, beta-blockers, ACE inhibitors or ARBs, chronic antiplatelet agents, diuretics, statins, digoxin, and calcium channel blockers). Patients had at least one ECG-documented AF/AFL episode during the 3 months prior to study entry but were in sinus rhythm for at least one hour. Patients ranged in age from 20 to 88 years, with the majority being Caucasian (97%), male (70%) patients. The most common co-morbidities were <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (56.8%) and structural heart disease (41.5%), including coronary heart disease (21.8%). Patients were followed for 12 months.</p>
<p>In the pooled data from EURIDIS and ADONIS as well as in the individual trials, dronedarone delayed the time to first recurrence of AF/AFL (primary endpoint), lowering the risk of first AF/AFL recurrence during the 12-month study period by about 25%,with an absolute difference in recurrence rate of about 11% at 12 months. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 ANDROMEDA</h2>
<p class="First">Patients recently hospitalized with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and severe left ventricular systolic dysfunction (wall motion index ≤1.2) were randomized to either MULTAQ 400 mg twice daily or matching placebo, with a primary composite end point of all-cause mortality or hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Patients enrolled in ANDROMEDA were predominantly NYHA Class II (40%) and III (57%), and only 25% had AF at randomization. After enrollment of 627 patients and a median follow-up of 63 days, the trial was terminated because of excess mortality in the dronedarone group. Twenty-five (25) patients in the dronedarone group died versus 12 patients in the placebo group (hazard ratio 2.13; 95% CI: 1.07 to 4.25). The main reason for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. There were also excess hospitalizations for cardiovascular reasons in the dronedarone group (71 versus 51 for placebo) <span class="Italics">[see <a href="#BOX">Boxed Warning</a> and <a href="#S4">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.4"></a><a name="section-13.4"></a><p></p>
<h2>14.4 PALLAS </h2>
<p class="First">Patients with permanent AF (AF documented in 2 weeks prior to randomization and at least 6 months prior to randomization in whom cardioversion had failed or was not planned) and additional risk factors for <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> (<span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, prior <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA, symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, LVEF &lt;40%, <span class="product-label-link" type="condition" conceptid="317309" conceptname="Peripheral arterial occlusive disease">peripheral arterial occlusive disease</span>, or age &gt;75 with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) were randomized to dronedarone 400 mg twice daily or placebo. </p>
<p>After enrollment of 3236 patients (placebo=1617 and dronedarone=1619) and a median follow up of 3.7 months days for placebo and 3.9 for dronedarone, the study was terminated because of a significant increase in </p>
<ul>
<li>Mortality: 25 dronedarone vs. 13 placebo (HR, 1.94; CI, 0.99 to 3.79). The majority of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the dronedarone group were classified as arrhythmic/<span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden deaths</span> (HR, 3.26; CI: 1.06 to 10.0). Baseline digoxin therapy was reported in 11/13 dronedarone patients who died of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. None of the arrhythmic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> on placebo (4) reported use of digoxin. </li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>: 23 dronedarone vs. 10 placebo (HR, 2.32; CI: 1.11 to 4.88). The increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> observed with dronedarone was observed in the first two weeks of therapy (10 dronedarone vs. 1 placebo), most of the  subjects treated with dronedarone did not have an INR of 2.0 to 3.0.[<span class="Italics">see <a href="#S5.3">Warning and Precaution (5.3)</a></span>] </li>
<li>Hospitalizations for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in the dronedarone group: 43 dronedarone vs. 24 placebo (HR, 1.81; CI: 1.10 to 2.99).</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">MULTAQ 400-mg tablets are provided as white film-coated tablets for oral administration, oblong-shaped, engraved with a double wave marking on one side and "4142" code on the other side in:</p> Bottles of 60 tablets,      NDC 54868-3086-0<br><div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at 25°C (77°F): excursions permitted to 15–30°C (59–86°F), [see USP controlled room temperature]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Information for Patients</h2>
<p class="First"><span class="Italics">[See <a href="#S17.2">Medication Guide (17.2)</a>]</span></p>
<p>MULTAQ should be administered with a meal. Warn patients not to take MULTAQ with grapefruit juice. </p>
<p>If a dose is missed, patients should take the next dose at the regularly scheduled time and should not double the dose. </p>
<p>Advise patients to consult a physician if they develop signs or symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> such as acute <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">dependent edema</span>, or increasing <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>.</p>
<p>Advise patients to immediately report any symptoms of potential <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> (such as <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, dark urine or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>) to their physician.</p>
<p>Advise patients to inform their physician of any history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, rhythm disturbance other than <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> or flutter or predisposing conditions such as uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p>MULTAQ may interact with some drugs; therefore, advise patients to report to their doctor the use of any other prescription, non-prescription medication or herbal products, particularly St. John's wort. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Medication Guide</h2>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Medication Guide<br>MULTAQ (MUL-tak)<br>(dronedarone) Tablets</span></p>
<p>Read this Medication Guide before you start taking MULTAQ and each time you get a refill. There may be new information.  This information does not take the place of talking with your doctor about your medical condition or your treatment.  </p>
<p><span class="Bold">What is the most important information I should know about MULTAQ?</span></p>
<dl>
<dt class="Bold">1.</dt>
<dd>
<span class="Bold">MULTAQ is not for people with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with symptoms which recently worsened or for people with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.  People with these conditions who take MULTAQ have an increased chance of dying.</span>  <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> means your heart does not pump blood through your body as well as it should.</dd>
</dl>
<p><span class="Bold">Do not take MULTAQ if you have symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> which recently worsened or if you have severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </span></p>
<p>Call your doctor right away if you have any signs and symptoms of  <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> at rest</li>
<li><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span> or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up frothy <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> at rest, nighttime or after minor exercise</li>
<li>trouble sleeping or waking up at night because of breathing problems</li>
<li>using more pillows to prop yourself up at night so you can breathe more easily</li>
<li>gaining more than 5 pounds quickly</li>
<li>increasing <span class="product-label-link" type="condition" conceptid="133299" conceptname="Swelling of limb">swelling of feet</span> or legs</li>
</ul>
<dl>
<dt class="Bold">2.</dt>
<dd>
<span class="Bold">MULTAQ is not for people with a type of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (irregular heart rhythm) called permanent <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (AF).</span>  In permanent AF<span class="Bold">,</span> your heartbeat stays in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and will not or cannot be changed back to a normal rhythm. Your doctor will monitor your heart rhythm regularly to make sure your heartbeat keeps a normal rhythm.</dd>
</dl>
<p><span class="Bold">Do not take MULTAQ if you have permanent AF.</span></p>
<p>Call your doctor right away if you notice that your pulse is irregular. This is a sign that you are in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>. </p>
<dl>
<dt class="Bold">3.</dt>
<dd>
<span class="Bold">MULTAQ may cause liver problems, including life-threatening <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>.</span>  Your doctor may order blood tests to check your liver before you start taking MULTAQ and during treatment. In some cases MULTAQ treatment may need to be stopped. Tell your doctor right away if you develop any of these signs and symptoms of liver problems: <ul>
<li>loss of appetite, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">feeling unwell</span>, unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>yellowing of the skin or the whites of the eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) </li>
<li>unusual darkening of the urine</li>
<li>right upper stomach area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> </li>
</ul>
</dd>
</dl>
<p><span class="Bold">What is MULTAQ?</span></p>
<p>MULTAQ is a prescription medicine used to lower the chance that you would need to go into the hospital for <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>. It is meant for people who have had <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> in the past but are now in normal rhythm. </p>
<p>It is not known if MULTAQ is safe and effective in children younger than age 18 years old.</p>
<p><span class="Bold">Who should not take MULTAQ?</span></p>
<p><span class="Bold">See "<a href="#Important">What is the most important information I should know about taking MULTAQ?</a>"</span></p>
<p><span class="Bold">Do not take MULTAQ if:</span></p>
<ul class="Disc">
<li><span class="Bold">You are in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and your doctor is not planning to change you back into normal rhythm</span></li>
<li><span class="Bold">You have symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> which recently worsened or you have severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> </span></li>
<li><span class="Bold">You have severe liver problems or had liver problems after using amiodarone (a medicine for abnormal heart rhythm)</span></li>
<li>
<span class="Bold">You take certain medicines that can change the amount of MULTAQ that gets into your body.  Do not use these medicines with MULTAQ:</span><ul class="Circle">
<li>Nefazodone for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>Norvir<span class="Sup">®</span> (ritonavir) for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> </li>
<li>Nizoral<span class="Sup">®</span> (ketoconazole), and Sporanox<span class="Sup">®</span> (itraconazole), and Vfend<span class="Sup">®</span> (voriconazole) for <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span></li>
<li>Ketek<span class="Sup">®</span> (telithromycin), Biaxin<span class="Sup">®</span> (clarithromycin) for <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span></li>
<li>Cyclosporine for organ transplant</li>
</ul>
</li>
<li>
<span class="Bold">You take certain medicines that can lead to a dangerous abnormal heart rhythm:</span><ul class="Circle">
<li>Some medicines for mental illness called phenothiazines </li>
<li>Some medicines for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> called tricyclic antidepressants  </li>
<li>Some medicines for abnormal heart rhythm or fast heartbeat</li>
<li>Some medicines for <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span></li>
</ul>Ask your doctor if you are not sure if your medicine is one that is listed above. 							</li>
<li>
<span class="Bold">You are pregnant or plan to become pregnant. </span>  It is not known if MULTAQ will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. <ul class="Disc"><li>Women who may become pregnant should use effective birth control (contraception) while taking MULTAQ.  Talk to your doctor about the best birth control methods for you. </li></ul>
</li>
<li>
<span class="Bold">You are breast-feeding or plan to breastfeed. </span> It is not known if MULTAQ passes into your breast milk. You and your doctor should decide if you will take MULTAQ or breastfeed. You should not do both.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before starting MULTAQ?</span></p>
<ul class="Disc">
<li>If you have any other heart problems</li>
<li>Tell your doctor about all the medicines you take, including any new medicines.  Include all prescription and non-prescription medicines, vitamins and herbal remedies. MULTAQ and certain other medicines can react with each other, causing serious side effects. <span class="Bold">Know the medicines you take</span>.  Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.</li>
</ul>
<p><span class="Bold">Be sure to tell your doctor and pharmacist if you take: </span></p>
<ul class="Disc">
<li>medicine for high blood pressure, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, or other heart conditions</li>
<li>statin medicine to lower blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></li>
<li>medicine for TB (<span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>)</li>
<li>medicine for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
<li>medicine for organ transplant</li>
<li>herbal supplement called St. John's wort</li>
</ul>
<p>Some of these medicines could keep MULTAQ from working well or make it more likely for you to have side effects.</p>
<p><span class="Bold">How should I take MULTAQ?</span></p>
<ul class="Disc">
<li>Take MULTAQ exactly as your doctor tells you.</li>
<li>Take MULTAQ two times a day with food, once with your morning meal and once with your evening meal.   </li>
<li>Do not stop taking MULTAQ even if you are feeling well for a long time. The medicine may be working.</li>
<li>If you miss a dose, wait and take your next dose at your regular time. Do not take 2 doses at the same time. Do not try to make up for a missed dose.</li>
</ul>
<p><span class="Bold">What should I avoid while taking MULTAQ?</span></p>Do not drink grapefruit juice while you take MULTAQ. Grapefruit juice can increase the amount of MULTAQ in your blood and increase the likelihood that you will have a side effect of MULTAQ.<p><span class="Bold"> What are the possible side effects of MULTAQ?</span></p>
<p>MULTAQ may cause serious side effects, including:</p>
<ul class="Disc">
<li>See "<span class="Bold"><a href="#important">What is the most important information I should know about MULTAQ?</a>"</span>
</li>
<li>Slowed heartbeat (<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>)</li>
</ul>
<p>The most common side effects of MULTAQ include:</p>
<ul class="Disc">
<li>Stomach problems such as <ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span></li>
</ul>
</li>
<li>feeling tired and weak</li>
<li>skin problems such as <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
</ul>
<p>Tell your doctor about any side effect that bothers you or that does not go away. These are not all the possible side effects of MULTAQ. For more information ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store MULTAQ?</span></p>
<p>Store MULTAQ at room temperature (59–86°F or 15–30°C). </p>
<p><span class="Bold">Keep MULTAQ and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about MULTAQ</span></p>
<p>Medicines are sometimes used for purposes not mentioned in a Medication Guide. Do not use MULTAQ for a condition for which it was not prescribed. Do not give MULTAQ to other people, even if they have the same symptoms or condition. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about MULTAQ. If you would like more information:</p>
<ul class="Disc">
<li>Talk with your doctor</li>
<li>Ask your doctor or pharmacist for information about MULTAQ that was written for health-care professionals</li>
<li>For the latest information and Medication Guide, visit www.sanofi-aventis.us or call sanofi-aventis Medical Information Services at 1-800-633-1610 option 1. The Medication Guide may have changed since this copy was printed.</li>
</ul>
<p><span class="Bold">What are the ingredients in MULTAQ?</span></p>
<p><span class="Bold">Active ingredient:</span> dronedarone </p>
<p><span class="Bold">Inactive ingredients:  </span>hypromellose, starch, crospovidone, poloxamer 407, lactose monohydrate, colloidal silicon dioxide, magnesium stearate  polyethylene glycol 6000, titanium dioxide, carnauba wax </p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.<br>Issued December 2011</p>
<p>Manufactured by Sanofi Winthrop Industrie<br>1, rue de la Vierge<br>33440 Ambares, France</p>
<p>©sanofi-aventis, 2011<br>All rights reserved. </p>
<p>MULTAQ is a trademark of sanofi-aventis.</p>
<p>The brands listed are the registered trademarks of their respective owners and are not trademarks of sanofi-aventis U.S. LLC.</p>
<p>sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First">Additional bar code label applied by:<br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma       74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 60 Tablet Bottle</span></p>
<p><img alt="PRINCIPAL DISPLAY PANEL - 60 Tablet Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=236d4549-f44b-4677-b857-acedd10b9920&amp;name=3086.jpg"></p>
<p><span class="Bold">Rx ONLY</span></p>
<p><span>MULTAQ<span class="Sup">®</span></span><br>(dronedarone)<br><span class="Bold">Tablets 400</span>mg</p>
<p><span class="Bold">Dispense with Medication Guide.</span></p>
<p><span class="Bold">60 </span>Tablets</p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MULTAQ 		
					</strong><br><span class="contentTableReg">dronedarone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3086(NDC:0024-4142)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Dronedarone</strong> (Dronedarone) </td>
<td class="formItem">Dronedarone</td>
<td class="formItem">400 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>poloxamer 407</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>carnauba wax</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">4142</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3086-0</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022425</td>
<td class="formItem">02/23/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>66ea5793-f691-4217-9a37-39690a7a3f69</div>
<div>Set id: 236d4549-f44b-4677-b857-acedd10b9920</div>
<div>Version: 2</div>
<div>Effective Time: 20111228</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
